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Purpose: The purpose of this study was to elucidate prognostic factors for survival and 
clinical outcomes of urological soft tissue sarcomas (STSs). 
Materials and Methods: This was a retrospective review of the medical records of 48 
patients with urological STS treated from January 1982 to July 2009. Demographic 
and pathological characteristics were compared. Patients' demographics, clin-
ico-pathological parameters, overall survival, and the factors expected to predict sur-
vival, such as sex, age at diagnosis, primary organ, surgical resection, metastasis, and 
mass size, were analyzed. We evaluated differences in survival on the basis of histo-
logical subtype by Kaplan-Meier analysis and multivariate Cox proportional hazards 
regression.
Results: The study included 34 males (70.8%) and 14 females (29.1%). The mean age 
at diagnosis was 47.1 years (range, 3 to 80). The most common site was the retro-
peritoneum (n=16), followed by the kidney (n=12), prostate (n=10), bladder (n=7), ure-
ter (n=1), and paratesticular region (n=1). Nineteen patients (39.5%) had other organ 
metastases at diagnosis. The most common subtypes of sarcoma were leiomyosarcoma 
(50%), rhabdomyosarcoma (18.7%), and liposarcoma (8%). The remaining 11 cases had 
other histological subtypes (22.9%). Mean tumor size was 9.5 cm (range, 2.2 to 24). 
Thirty-three patients (68.7%) underwent surgical resection. The overall survival rate 
at 5 years was 51.4%. In the univariate and multivariate analysis, surgical resection, 
primary tumor site, and metastasis at diagnosis remained significant predictors of 
prognosis. Patients with retroperitoneal sarcoma had a higher overall survival rate by 
5 years compared with patients with other organ sarcoma.
Conclusions: The overall survival rate at 5 years was 51.4%. Surgical resection, primary 
tumor site, and metastasis at diagnosis remained significant predictors of prognosis.
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INTRODUCTION
Soft tissue sarcomas (STSs) are a heterogeneous group of 
solid tumors that arise from embryonic mesenchymal cells 
and that have distinct clinical and pathological features. 
Microscopically, carcinosarcomas are biphasic tumors 
comprising an intimate admixture of carcinomatous and 
sarcomatous components with an abrupt or gradual tran-
sition from one to the other. STSs of the genitourinary (GU) 
tract are relatively rare, accounting for only 2.1% of all 
STSs and 1% to 2% of all malignant GU tumors [1-3]. 
Because of the rarity of urological STSs, clinical data are 
limited and prognosis is often considered unpredictable 
[4,5]. Recently, several groups have reported their long- 
term experiences with GU STSs and have investigated 
prognosis and prognostic factors [4-6]. Although the con-
sensus is that total surgical resection provides the patient 
the best chance for cure [2,7], there is no universal agree-Korean J Urol 2011;52:669-673
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TABLE 1. Characteristics of patients with urological soft tissue 
sarcomas
Variable
Patients
Mean age (yr)
Gender
　Male
　Female 
Primary organ
　Retroperitoneum
　Kidney
　Prostate
　Bladder
　Paratesticular area
　Ureter
Histological subtype
　Leiomyosarcoma
　Rhabdomyosarcoma
　Liposarcoma
　Others
Tumor size (largest dimension)
　＜5 cm
　＞5 cm
Metastasis at diagnosis
　Yes
　No
Surgical resection
　Yes
　No
Mean follow-up (mo)
48
47.1 (3-80)
34 (70.8)
14 (29.1)
16 (33.3)
12 (25.0)
10 (20.8)
7 (14.5)
1 (2.0)
1 (2.0)
24 (50.0)
9 (18.7)
4 (8.0)
11 (22.9)
5 (10.4)
43 (89.5)
19 (39.5)
29 (60.4)
33 (68.7)
15 (31.2)
43.6 (6-167)
Values are presented number (%)
ment concerning prognostic factors for GU STSs. Several 
analyses of prognostic factors influencing the overall sur-
vival (OS) of patients with GU STSs have revealed that tu-
mor stage, grade, size, and anatomic site are important for 
patient survival. 
　To the best of our knowledge, no prior study has inves-
tigated clinical outcomes and prognostic factors of GU 
STSs in a Korean patient population. In this study, we in-
vestigated prognostic factors of GU STSs on the basis of 28 
years of experience with these tumors at a single center in 
Korea. 
MATERIALS AND METHODS
1. Patients
Between January 1982 and July 2009, 48 patients who 
were histologically diagnosed with a GU STS at our in-
stitute were included in this study. Sarcomas of the GU 
tract that originated from the kidney, ureter, bladder, pros-
tate, paratesticular region, and retroperitoneum were 
included. Sarcomas that originated from female genital or-
gans such as the uterus, ovary, vulva, or vagina were ex-
cluded from this study. 
2. Variables
Demographic and clinical data were retrieved by reviewing 
patients’ charts, clinical data, operative notes, radiological 
reports, and pathological reports. The variables analyzed 
were patient age, sex, tumor histology, tumor size, primary 
organ, metastasis at diagnosis, and status of surgical 
resection. The primary histopathological categories were 
liposarcoma, leiomyosarcoma, rhabdomyosarcoma, and 
other STSs. Tumors were divided into two groups on the 
basis of size: one group comprised tumors smaller than 5 
cm, and the other comprised tumors larger than 5 cm. Local 
recurrence or metastasis was defined as the first re-
currence of disease at the primary tumor site or distant site 
detected by a radiographic modality, such as computed 
tomography. Morbidity and mortality analyses were con-
ducted by reviewing patient charts and clinical records.
3. Statistical analysis
Univariate analysis of variables to determine prognostic 
factors was performed by using the log rank test. Multivar-
iate analysis was performed by using the Cox proportional 
hazards model. The results of the Cox model analysis are 
reported as hazard ratios and 95% confidence intervals. The 
Kaplan-Meier estimate of the survival curve was used to 
summarize the data, whereas differences between patient 
groups were assessed by the log rank test. Statistical sig-
nificance was defined as a p＜0.05. All statistical tests were 
performed by using PASW ver. 18.0 software.
RESULTS
1. Patient characteristics
During the study period, 48 patients with GU STSs were 
treated at our institution. The patients’ characteristics are 
shown in Table 1. There were 14 females (29.1%) and 34 
males (70.8%). The mean age at diagnosis was 47.1 years 
(range, 3 to 80 years). The mean follow-up duration was 
43.6 months (range, 6 to 167 months). The most common 
site was the retroperitoneum (n=16, 33.3%) followed by the 
kidney (n=12, 25%), prostate (n=10, 20.8%), bladder (n=7, 
14.5%), ureter (n=1, 2%), and paratesticular region (n=1, 
2%). The mean tumor size was 9.5 cm (range, 2.2 to 24 cm) 
and 43 patients (89.5%) had tumors larger than 5 cm. 
Nineteen patients (39.5%) had other organ metastases at 
diagnosis. The histological subtypes of sarcoma were as fol-
lows: leiomyosarcoma (24, 50%), rhabdomyosarcoma (9, 
18.7%), and liposarcoma (4, 8%). The remaining 11 cases 
had other histological subtypes (22.9%). Of the 48 patients, 
33 (68.7%) underwent surgical resection and 15 (31.2%) 
were treated by chemotherapy, radiotherapy, or both. 
2. Survival
At the time of analysis, 20 patients (41.6%) had died of their 
STS, 2 patients (4.1%) had died of unrelated causes, and 
26 patients (54.1%) were alive. The OS rate at 5 years was 
51.4% (Fig. 1). The OS rate of inoperable cases at 5 years 
was 38%. The 5-year estimated survival rate of patients 
with a retroperitoneal sarcoma was 82%, while that of pa-Korean J Urol 2011;52:669-673
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FIG. 1. Kaplan-Meier analysis of disease specific survival in all 
patients.
FIG. 2. Kaplan-Meier analysis of overall survival according to 
presence vs. abscence of metastasis at diagnosis.
FIG. 3. Kaplan-Meier analysis of overall survival according to 
surgical resection or not.
FIG. 4. Kaplan-Meier analysis of overall survival according to 
primary organ.
TABLE 2. Univariate and multivariate analyses of prognostic factors
Risk factors
Univariate Multivariate
Hazards ratio 
(95% CI)
p-value
Hazards ratio 
(95% CI)
p-value
Age (< 60 vs. >60 yr)
Gender (male vs. female) 
Primary organ
 (retroperitoneum vs. other organ)
Tumor size (＜5 cm vs. ＞5 cm)
Metastasis at diagnosis
Surgical resection
Histological subtype
 0.837 (0.344-2.827)
1.041 (1.202-2.785)
4.317 (1.440-13.089)
0.814 (0.197-3.584)
5.051 (2.024-12.745)
12.517 (4.179-37.816)
0.81 (0.191-3.524)
0.068
0.079
 0.009
0.781
＜0.001
＜0.001
0.785
-
-
2.584 (1.017-7.647)
-
3.614 (1.433-9.092)
9.711 (3.238-29.418)
-
-
-
0.048
-
0.007
＜0.001
-
CI: confidence interval
tients with a bladder sarcoma was 73%. The 5-year esti-
mated survival rate for patients who presented with pros-
tate sarcoma was 44%, while that for patients who pre-
sented with renal sarcoma was 39%.
3. Prognostic factors
There were no significant differences in survival according 
to age (p=0.79), gender (p=0.84), tumor size (p=0.59), or his-
tological subtype (p=0.69) according to the univariate anal-
ysis (Table 2). However, a significant difference in survival 
according to metastasis at diagnosis was observed (Fig. 2). Korean J Urol 2011;52:669-673
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Patients who underwent surgical resection also showed 
significantly better overall survival (Fig. 3). Patients with 
retroperitoneal sarcomas had more favorable survival out-
comes than did patients with bladder, kidney, or prostate 
sarcomas (Fig. 4). These three factors (metastasis, surgical 
resection, and primary organ) were also significantly asso-
ciated with improved overall survival in the multivariate 
analysis (Table 2).
DISCUSSION
STSs of the GU tract are rare. Less than 5% of STSs arise 
in the GU tract and only 15% of STSs arise within the 
retroperitoneum. The rarity of GU STS is a major obstacle 
to clinical research; contemporary data in the medical liter-
ature are limited. Several earlier clinical studies have in-
vestigated urological STSs. Mondaini et al reviewed sarco-
mas of different histological types in a multicenter study 
involving eight different hospitals in Tuscany, Italy [5]. 
The MSKCC group reported two consecutive series, one in-
cluding 43 patients treated between 1982 and 1989 and an-
other including 131 patients treated between 1977 and 
2003 [2]. The latter study was an extension of the former 
study with a prolonged follow-up. Prognostic factors for lo-
cal recurrence-free and disease-specific survival were de-
termined [8]. Owing to the rareness of STSs, and therefore 
the absence of randomized controlled trials, no standard 
treatment options for this disease exist. Conventional 
treatment options for STSs include wide margin surgery 
and radiotherapy. This multimodal approach has replaced 
amputation as the primary surgical treatment of choice.
　In the present study, we analyzed the clinicopathological 
features of GU STSs and investigated prognostic factors. 
The mean tumor size of 9.5 cm found in the present study 
is slightly smaller than that reported previously [9-11]. The 
5-year OS was 51.4%, similar to the results of previous 
studies that reported 5-year OS rates of 50% [10,12]. 
　Several studies have examined predictors of outcome in 
patients with GU STSs. Dotan et al reported that the pres-
ence of metastasis and rhabdomyosarcoma were un-
favorable prognostic variables [8]. In our study, the pres-
ence of metastasis at diagnosis was associated with surviv-
al in both univariate and multivariate analyses. However, 
no significant difference was detected among the histo-
logical subgroups in this study. Lewis et al reported that 
the presence of unresectable disease and incomplete surgi-
cal resection were the most significant factors predictive 
of disease-specific death [13]. In a study by van Dalen et 
al of 143 patients treated in the Netherlands, complete tu-
mor resection was correlated with better overall survival 
in the multivariate analysis [14]. However, Dotan et al re-
ported that complete resection was not a significant factor 
predictive of disease-specific survival in univariate and 
multivariate analysis in 102 patients with primary tumors 
only [15]. These results suggest that any type of surgical 
resection can provide the best chance of survival in patients 
presenting with primary disease or with primary and 
metastatic disease. Consistent with this, we found that the 
absence of surgical resection was an unfavorable prog-
nostic variable for overall survival. Therefore, we suggest 
that surgical resection may contribute to a favorable prog-
nosis in patients with urological STSs.
　The prognosis of retroperitoneal STSs has been reported 
to be more favorable than that of the other GU STSs. 
Disease prognosis was the worst for STSs of the kidney, 
whereas the prognosis was better for retroperitoneum, 
bladder, and prostate sarcomas, as reported previously [7]. 
　According to a previous study, the size of STSs is an im-
portant prognostic variable [16], in contrast with our find-
ings. This discrepancy may be because STSs arising from 
the retroperitoneum can attain a large size owing to the 
flexibility of the retroperitoneum. However, retroperito-
neal STSs showed a better prognosis than bladder, pros-
tate, and renal STSs in our study. 
　The histological subtype of the GU STSs was not a prog-
nostic factor for disease-specific survival in either the uni-
variate or the multivariate analysis; in other words, we did 
not observe an association between histological subtype 
and disease-specific survival. However, the small number 
of patients in each group made statistical comparisons 
difficult.
CONCLUSIONS
Genitourinary sarcomas are a rare group of tumors with 
a generally poor prognosis. The overall survival rate at 5 
years was 51.4%. Surgical resection, metastasis at diag-
nosis, and the primary organ were significant predictors of 
prognosis. Retroperitoneal STSs had more favorable out-
comes than bladder, prostate, and renal STSs. The data 
presented in this study contribute to our understanding of 
urological STSs and may help in the development of an opti-
mal therapeutic strategy to treat STSs.
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